Previous 10 | Next 10 |
IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for the sixth consecutive year. ...
IQVIA ( NYSE: IQV ) is scheduled to announce Q4 earnings results on Friday, February 10th, before market open. The consensus EPS Estimate is $2.76 (+8.2% Y/Y) and the consensus Revenue Estimate is $3.71B (+1.9% Y/Y). Over the last 2 years, IQV has beaten EPS estimates 100%...
The shares for Doximity (NYSE: DOCS) , Iqvia Holdings (NYSE: IQV) , and TransMedics Group (NASDAQ: TMDX) are all off to positive starts this year, but what makes them different from other companies is that they are changing healthcare industry standards. Doximity i...
Summary William von Mueffling's 13F portfolio value increased this quarter from $11.04B to $11.81B. Cantillon added CDW Corp and increased BlackRock, Interactive Brokers, Entegris, and Armstrong World Industries during the quarter. The portfolio continues to be very concentrated wit...
IQVIA ( NYSE: IQV ) announces the first life sciences industry collaboration with Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, in China. The two companies will be providing solutions hosted in Mainland China leveraging Salesforce on Alibab...
Leading technology providers come together to bring innovative solutions addressing the unique business and compliance needs of the Greater China Region IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the ...
Summary IQVIA continues to demonstrate its propensity to generate growth and future value for shareholders. Here, we peel back the layers to demonstrate the underlying economics in the company's business model. Simply, it appears that IQV can continue funding its future growth initi...
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. Th...
Summary IQVIA is one of my favorite investments thanks to it being one of the leading CROs with a broad array of services. IQVIA has over 10,000 customers including big pharma. I was concerned IQVIA was going to struggle following the pandemic, but they have continued to deliver strong ...
The COVID-19 pandemic continues to impact pharmaceutical markets globally, and is estimated to expand the net cumulative pharmaceutical market by $500 billion from 2020 through 2027 Highest volume growth is expected in Latin America, Asia and Africa, driven by a mix of population growth and e...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...